Children's Oncology Group's 2013 blueprint for research: Bone tumors |
| |
| Authors: | Richard Gorlick MD Katherine Janeway MD Stephen Lessnick MD PhD Neyssa Marina MD |
| |
| Affiliation: | 1. The Department of Pediatrics and Molecular Pharmacology, The Albert Einstein College of Medicine of Yeshiva University, Bronx, New York;2. The Division of Pediatric Hematology‐Oncology, The Children's Hospital at Montefiore, Bronx, New York;3. Department of Pediatric Hematology‐Oncology, Dana‐Farber/Children's Hospital Cancer Center, Boston, Massachusetts;4. Division of Pediatric Hematology/Oncology, Department of Oncological Sciences, University of Utah School of Medicine, Center for Children's Cancer Research at Huntsman Cancer Institute, Salt Lake City, Utah;5. Pediatric Hematology/Oncology, Lucile Packard Children's Hospital & Stanford University, Palo Alto, California |
| |
| Abstract: | In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five‐year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval‐compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval‐compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF‐1R and mTOR in ES, and RANKL and GD2 in osteosarcoma. Pediatr Blood Cancer 2013; 60: 1009–1015. © 2012 Wiley Periodicals, Inc. |
| |
| Keywords: | blueprint bone sarcoma Ewing sarcoma osteosarcoma |
|
|
